
Sign up to save your podcasts
Or


GLP-1 drugs like Ozempic, Wegovy, and Mounjaro have opened doors for people to lose weight. Should everyone have the option to take it? Those arguing “yes” say obesity needs to be treated using every available tool, especially for people for whom diet, lifestyle changes, and exercise aren’t enough. Those arguing “no” are concerned about its side effects and the risks if people don’t take them as directed. Now we debate: should prescription weight loss drugs be available for all?
Arguing Yes: David Allison, Obesity Researcher; Dean and Distinguished Professor at the Indiana University School of Public Health-Bloomington
Arguing No: Stuart W. Flint, Associate Professor of the Psychology of Obesity at the University of Leeds
Emmy award-winning journalist John Donvan moderates
Learn more about your ad choices. Visit podcastchoices.com/adchoices
By Open to Debate4.6
21142,114 ratings
GLP-1 drugs like Ozempic, Wegovy, and Mounjaro have opened doors for people to lose weight. Should everyone have the option to take it? Those arguing “yes” say obesity needs to be treated using every available tool, especially for people for whom diet, lifestyle changes, and exercise aren’t enough. Those arguing “no” are concerned about its side effects and the risks if people don’t take them as directed. Now we debate: should prescription weight loss drugs be available for all?
Arguing Yes: David Allison, Obesity Researcher; Dean and Distinguished Professor at the Indiana University School of Public Health-Bloomington
Arguing No: Stuart W. Flint, Associate Professor of the Psychology of Obesity at the University of Leeds
Emmy award-winning journalist John Donvan moderates
Learn more about your ad choices. Visit podcastchoices.com/adchoices

32,253 Listeners

30,694 Listeners

43,619 Listeners

5,142 Listeners

10,736 Listeners

775 Listeners

26,414 Listeners

4,275 Listeners

2,453 Listeners

1,112 Listeners

2,391 Listeners

7,247 Listeners

16,482 Listeners

30 Listeners

16,493 Listeners